Monroe Bank & Trust’s Charles River Laboratories CRL Stock Holding History

Monroe Bank & Trust’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$976K	Buy	+6,881	New	+$933K	0.33%	57

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Monroe Bank & Trust's CRL Position: Q2 2019 in Review

Monroe Bank & Trust opened a new position in Charles River Laboratories (CRL) in Q2 2019: 6,881 shares worth $976K. The stake represents 0.33% of the portfolio and ranks #57 among its holdings.

405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

Monroe Bank & Trust held 6,881 shares of Charles River Laboratories worth $976K as of Q2 2019.
Charles River Laboratories was a new Monroe Bank & Trust position in Q2 2019.
Charles River Laboratories made up 0.33% of Monroe Bank & Trust's portfolio in Q2 2019, its #57 holding.
405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Monroe Bank & Trust's 13F filing for Q2 2019, filed 29 Jul 2019.